The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Trivalent Inactivated Influenza Vaccine Market Research Report 2025
Synopsis
The global Trivalent Inactivated Influenza Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Trivalent Inactivated Influenza Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Trivalent Inactivated Influenza Vaccine.
Report Scope
The Trivalent Inactivated Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Trivalent Inactivated Influenza Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Trivalent Inactivated Influenza Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Sanofi S.A
Abbott
GlaxoSmithKline
Merck
Novartis
Pfizer
Serum Institute of India
CSL Limited
Segment by Type
Nasal Spray
Intramuscular Injection
Intradermal Injection
Segment by Application
Hospital
Clinic
Public Health Agency
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Trivalent Inactivated Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Trivalent Inactivated Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Trivalent Inactivated Influenza Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Trivalent Inactivated Influenza Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Trivalent Inactivated Influenza Vaccine.
Report Scope
The Trivalent Inactivated Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Trivalent Inactivated Influenza Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Trivalent Inactivated Influenza Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Sanofi S.A
Abbott
GlaxoSmithKline
Merck
Novartis
Pfizer
Serum Institute of India
CSL Limited
Segment by Type
Nasal Spray
Intramuscular Injection
Intradermal Injection
Segment by Application
Hospital
Clinic
Public Health Agency
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Trivalent Inactivated Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Trivalent Inactivated Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Trivalent Inactivated Influenza Vaccine Market Overview
1.1 Product Overview and Scope of Trivalent Inactivated Influenza Vaccine
1.2 Trivalent Inactivated Influenza Vaccine Segment by Type
1.2.1 Global Trivalent Inactivated Influenza Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Nasal Spray
1.2.3 Intramuscular Injection
1.2.4 Intradermal Injection
1.3 Trivalent Inactivated Influenza Vaccine Segment by Application
1.3.1 Global Trivalent Inactivated Influenza Vaccine Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Public Health Agency
1.3.5 Others
1.4 Global Trivalent Inactivated Influenza Vaccine Market Size Estimates and Forecasts
1.4.1 Global Trivalent Inactivated Influenza Vaccine Revenue 2019-2030
1.4.2 Global Trivalent Inactivated Influenza Vaccine Sales 2019-2030
1.4.3 Global Trivalent Inactivated Influenza Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Trivalent Inactivated Influenza Vaccine Market Competition by Manufacturers
2.1 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Trivalent Inactivated Influenza Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Trivalent Inactivated Influenza Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Trivalent Inactivated Influenza Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Trivalent Inactivated Influenza Vaccine, Product Type & Application
2.7 Trivalent Inactivated Influenza Vaccine Market Competitive Situation and Trends
2.7.1 Trivalent Inactivated Influenza Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Trivalent Inactivated Influenza Vaccine Players Market Share by Revenue
2.7.3 Global Trivalent Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Trivalent Inactivated Influenza Vaccine Retrospective Market Scenario by Region
3.1 Global Trivalent Inactivated Influenza Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Trivalent Inactivated Influenza Vaccine Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2019-2030
3.2.1 Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2019-2024
3.2.2 Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2025-2030
3.3 Global Trivalent Inactivated Influenza Vaccine Global Trivalent Inactivated Influenza Vaccine Revenue by Region: 2019-2030
3.3.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Region: 2019-2024
3.3.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Region: 2025-2030
3.4 North America Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
3.4.1 North America Trivalent Inactivated Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2030)
3.4.3 North America Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
3.5.1 Europe Trivalent Inactivated Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2030)
3.5.3 Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Trivalent Inactivated Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
3.7.1 Latin America Trivalent Inactivated Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Trivalent Inactivated Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2019-2030)
4.1.1 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2019-2024)
4.1.2 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2025-2030)
4.1.3 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2019-2030)
4.2.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2019-2024)
4.2.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2025-2030)
4.2.3 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Trivalent Inactivated Influenza Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2019-2030)
5.1.1 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2019-2024)
5.1.2 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2025-2030)
5.1.3 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2019-2030)
5.2.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2019-2024)
5.2.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2025-2030)
5.2.3 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Trivalent Inactivated Influenza Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Trivalent Inactivated Influenza Vaccine Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Sanofi S.A
6.2.1 Sanofi S.A Corporation Information
6.2.2 Sanofi S.A Description and Business Overview
6.2.3 Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Portfolio
6.2.5 Sanofi S.A Recent Developments/Updates
6.3 Abbott
6.3.1 Abbott Corporation Information
6.3.2 Abbott Description and Business Overview
6.3.3 Abbott Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Abbott Trivalent Inactivated Influenza Vaccine Product Portfolio
6.3.5 Abbott Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Corporation Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck Trivalent Inactivated Influenza Vaccine Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Novartis Trivalent Inactivated Influenza Vaccine Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Trivalent Inactivated Influenza Vaccine Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Serum Institute of India
6.8.1 Serum Institute of India Corporation Information
6.8.2 Serum Institute of India Description and Business Overview
6.8.3 Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Portfolio
6.8.5 Serum Institute of India Recent Developments/Updates
6.9 CSL Limited
6.9.1 CSL Limited Corporation Information
6.9.2 CSL Limited Description and Business Overview
6.9.3 CSL Limited Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CSL Limited Trivalent Inactivated Influenza Vaccine Product Portfolio
6.9.5 CSL Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Trivalent Inactivated Influenza Vaccine Industry Chain Analysis
7.2 Trivalent Inactivated Influenza Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Trivalent Inactivated Influenza Vaccine Production Mode & Process
7.4 Trivalent Inactivated Influenza Vaccine Sales and Marketing
7.4.1 Trivalent Inactivated Influenza Vaccine Sales Channels
7.4.2 Trivalent Inactivated Influenza Vaccine Distributors
7.5 Trivalent Inactivated Influenza Vaccine Customers
8 Trivalent Inactivated Influenza Vaccine Market Dynamics
8.1 Trivalent Inactivated Influenza Vaccine Industry Trends
8.2 Trivalent Inactivated Influenza Vaccine Market Drivers
8.3 Trivalent Inactivated Influenza Vaccine Market Challenges
8.4 Trivalent Inactivated Influenza Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Trivalent Inactivated Influenza Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Trivalent Inactivated Influenza Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Trivalent Inactivated Influenza Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Trivalent Inactivated Influenza Vaccine Sales (K Doses) of Key Manufacturers (2019-2024)
Table 5. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Trivalent Inactivated Influenza Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Trivalent Inactivated Influenza Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Trivalent Inactivated Influenza Vaccine Average Price (US$/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Trivalent Inactivated Influenza Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Trivalent Inactivated Influenza Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Trivalent Inactivated Influenza Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Trivalent Inactivated Influenza Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Trivalent Inactivated Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Trivalent Inactivated Influenza Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Trivalent Inactivated Influenza Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Trivalent Inactivated Influenza Vaccine Sales by Region (2019-2024) & (K Doses)
Table 18. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Trivalent Inactivated Influenza Vaccine Sales by Region (2025-2030) & (K Doses)
Table 20. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Trivalent Inactivated Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 27. North America Trivalent Inactivated Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 28. North America Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Trivalent Inactivated Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Trivalent Inactivated Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 32. Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 33. Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Region (2019-2024) & (K Doses)
Table 37. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Region (2025-2030) & (K Doses)
Table 38. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Trivalent Inactivated Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 42. Latin America Trivalent Inactivated Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 43. Latin America Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Trivalent Inactivated Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2019-2024) & (K Doses)
Table 47. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2025-2030) & (K Doses)
Table 48. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Trivalent Inactivated Influenza Vaccine Sales (K Doses) by Type (2019-2024)
Table 51. Global Trivalent Inactivated Influenza Vaccine Sales (K Doses) by Type (2025-2030)
Table 52. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Trivalent Inactivated Influenza Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Trivalent Inactivated Influenza Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Trivalent Inactivated Influenza Vaccine Price (US$/Dose) by Type (2019-2024)
Table 59. Global Trivalent Inactivated Influenza Vaccine Price (US$/Dose) by Type (2025-2030)
Table 60. Global Trivalent Inactivated Influenza Vaccine Sales (K Doses) by Application (2019-2024)
Table 61. Global Trivalent Inactivated Influenza Vaccine Sales (K Doses) by Application (2025-2030)
Table 62. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Trivalent Inactivated Influenza Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Trivalent Inactivated Influenza Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Trivalent Inactivated Influenza Vaccine Price (US$/Dose) by Application (2019-2024)
Table 69. Global Trivalent Inactivated Influenza Vaccine Price (US$/Dose) by Application (2025-2030)
Table 70. AstraZeneca Corporation Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 73. AstraZeneca Trivalent Inactivated Influenza Vaccine Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Sanofi S.A Corporation Information
Table 76. Sanofi S.A Description and Business Overview
Table 77. Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 78. Sanofi S.A Trivalent Inactivated Influenza Vaccine Product
Table 79. Sanofi S.A Recent Developments/Updates
Table 80. Abbott Corporation Information
Table 81. Abbott Description and Business Overview
Table 82. Abbott Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Abbott Trivalent Inactivated Influenza Vaccine Product
Table 84. Abbott Recent Developments/Updates
Table 85. GlaxoSmithKline Corporation Information
Table 86. GlaxoSmithKline Description and Business Overview
Table 87. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product
Table 89. GlaxoSmithKline Recent Developments/Updates
Table 90. Merck Corporation Information
Table 91. Merck Description and Business Overview
Table 92. Merck Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Merck Trivalent Inactivated Influenza Vaccine Product
Table 94. Merck Recent Developments/Updates
Table 95. Novartis Corporation Information
Table 96. Novartis Description and Business Overview
Table 97. Novartis Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 98. Novartis Trivalent Inactivated Influenza Vaccine Product
Table 99. Novartis Recent Developments/Updates
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 103. Pfizer Trivalent Inactivated Influenza Vaccine Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Serum Institute of India Corporation Information
Table 106. Serum Institute of India Description and Business Overview
Table 107. Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 108. Serum Institute of India Trivalent Inactivated Influenza Vaccine Product
Table 109. Serum Institute of India Recent Developments/Updates
Table 110. CSL Limited Corporation Information
Table 111. CSL Limited Description and Business Overview
Table 112. CSL Limited Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 113. CSL Limited Trivalent Inactivated Influenza Vaccine Product
Table 114. CSL Limited Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Trivalent Inactivated Influenza Vaccine Distributors List
Table 118. Trivalent Inactivated Influenza Vaccine Customers List
Table 119. Trivalent Inactivated Influenza Vaccine Market Trends
Table 120. Trivalent Inactivated Influenza Vaccine Market Drivers
Table 121. Trivalent Inactivated Influenza Vaccine Market Challenges
Table 122. Trivalent Inactivated Influenza Vaccine Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Trivalent Inactivated Influenza Vaccine
Figure 2. Global Trivalent Inactivated Influenza Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Trivalent Inactivated Influenza Vaccine Market Share by Type in 2023 & 2030
Figure 4. Nasal Spray Product Picture
Figure 5. Intramuscular Injection Product Picture
Figure 6. Intradermal Injection Product Picture
Figure 7. Global Trivalent Inactivated Influenza Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Trivalent Inactivated Influenza Vaccine Market Share by Application in 2023 & 2030
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Public Health Agency
Figure 12. Others
Figure 13. Global Trivalent Inactivated Influenza Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Trivalent Inactivated Influenza Vaccine Market Size (2019-2030) & (US$ Million)
Figure 15. Global Trivalent Inactivated Influenza Vaccine Sales (2019-2030) & (K Doses)
Figure 16. Global Trivalent Inactivated Influenza Vaccine Average Price (US$/Dose) & (2019-2030)
Figure 17. Trivalent Inactivated Influenza Vaccine Report Years Considered
Figure 18. Trivalent Inactivated Influenza Vaccine Sales Share by Manufacturers in 2023
Figure 19. Global Trivalent Inactivated Influenza Vaccine Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Trivalent Inactivated Influenza Vaccine Players: Market Share by Revenue in 2023
Figure 21. Trivalent Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Trivalent Inactivated Influenza Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 24. North America Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 25. United States Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 28. Europe Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 29. Germany Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2019-2030)
Figure 36. China Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 46. Latin America Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Trivalent Inactivated Influenza Vaccine by Type (2019-2030)
Figure 56. Global Revenue Market Share of Trivalent Inactivated Influenza Vaccine by Type (2019-2030)
Figure 57. Global Trivalent Inactivated Influenza Vaccine Price (US$/Dose) by Type (2019-2030)
Figure 58. Global Sales Market Share of Trivalent Inactivated Influenza Vaccine by Application (2019-2030)
Figure 59. Global Revenue Market Share of Trivalent Inactivated Influenza Vaccine by Application (2019-2030)
Figure 60. Global Trivalent Inactivated Influenza Vaccine Price (US$/Dose) by Application (2019-2030)
Figure 61. Trivalent Inactivated Influenza Vaccine Value Chain
Figure 62. Trivalent Inactivated Influenza Vaccine Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
